European Commission approves Keytruda plus Padcev for adults with resectable muscle-invasive bladder cancer

MRK•2026-10-21

The European Commission approved Merck's Keytruda plus Padcev as perioperative treatment for adults with resectable muscle-invasive bladder cancer.

1. European approval

The European Commission approved Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) as perioperative treatment for adults with resectable muscle-invasive bladder cancer.

European Commission approves Keytruda plus Padcev for adults with resectable muscle-invasive bladder cancer

1. European approval

Related News

Valeo teams up with NVIDIA to develop autonomous driving computing platforms

Wabtec slips as Q3 revenue miss overshadows higher profit forecast

Ballard Power plans hydrogen power service expansion into US and Canada

Applied Digital, Soluna agree to joint venture for 50 MW AI data center in Texas

Accenture, TÜV SÜD partner to speed certification of industrial AI automation